Saturday, May 30, 2020 6:15:39 AM
Do you have a rationale? What is in play? Is it about the financing or non-appearance of Datalock PR?
I was playing daft, when I asked whether something was happening on Monday.
I'm not expecting anything to happen on Monday.
So why should we get hammered? A modest pullback wouldn't surprise, but why hammered?
By the way, I agree that it was just 1 or 2 buyers gradually accumulating over the last fortnight. I kind of hoped they had a bit more ammo to come. Maybe they have, maybe not. Perhaps a small hedge fund. And maybe an investment of around $5m (based on excess volume).
I don't think that the buying surge had anything to do with the L trial. But equally such investments are rarely made just on a whim..
So I'm still of the view that it was about something else.
And clever money buyers do not expect the share price to get hammered!
Financing was what it was. As I've said before, I'd rather see LP do a zero interest personal loan to the company. That would give all the right messages to shareholders. I expect she has the resources to do so.
But the fact remains they have to stay solvent. Nobody would thank them if they failed to do that.
And on datalock. They don't have to PR it. But why wouldn't they?
So I'm assuming it hasn't happened.
If there is a delay due to Covid restrictions on travel or access that compromises final query resolution and data scrub, they should just update us accordingly. Hardly difficult.
Because if they don't, as June progresses, shareholders who take timescales maybe a bit too literally, will start to get the niggles.
I was playing daft, when I asked whether something was happening on Monday.
I'm not expecting anything to happen on Monday.
So why should we get hammered? A modest pullback wouldn't surprise, but why hammered?
By the way, I agree that it was just 1 or 2 buyers gradually accumulating over the last fortnight. I kind of hoped they had a bit more ammo to come. Maybe they have, maybe not. Perhaps a small hedge fund. And maybe an investment of around $5m (based on excess volume).
I don't think that the buying surge had anything to do with the L trial. But equally such investments are rarely made just on a whim..
So I'm still of the view that it was about something else.
And clever money buyers do not expect the share price to get hammered!
Financing was what it was. As I've said before, I'd rather see LP do a zero interest personal loan to the company. That would give all the right messages to shareholders. I expect she has the resources to do so.
But the fact remains they have to stay solvent. Nobody would thank them if they failed to do that.
And on datalock. They don't have to PR it. But why wouldn't they?
So I'm assuming it hasn't happened.
If there is a delay due to Covid restrictions on travel or access that compromises final query resolution and data scrub, they should just update us accordingly. Hardly difficult.
Because if they don't, as June progresses, shareholders who take timescales maybe a bit too literally, will start to get the niggles.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
